Unit
Dermatologie | Venerologie | Allergologie
DERMA · Dept. IV
A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Safety Study of Xolair (Omalizumab) in Patients With Chronic Idiopathic Urticaria (CIU) Who Remain Symptomatic Despite Treatment With H1 Antihistamines, H2 Blockers, and/or Leukotriene Receptor Antagonists
Feb 19, 2012The study is a global Phase III, multicenter, randomized, double-blind, placebo controlled, parallel-group study to evaluate the safety and efficacy of omalizumab administered subcutaneously as an add-on therapy for the treatment of adolescent and ad...
Clinical Studies - Feb 19, 2012 - Jun 19, 2013
Automatically Closed
Project leader: Anliker Mark
Swiss Dermatology Network for Targeted Therapies (SDNTT) Objective Long-Term Benefits and Safety of Systemic Psoriasis Therapy: Swiss Registry on the Treatment of Psoriasis with Biologics and Systemic Therapeutics based on PsoBest German Registry and in operational cooperation with CVderm in Hamburg
Jan 31, 2012
Clinical Studies - Jan 31, 2012 - Dec 31, 2030
Ongoing
Project leader: Cozzio Antonio
A Phase 3, Multi Site, Randomized, Double Blind, Placebo Controlled, Parallel Group Study Of The Efficacy And Safety Of 2 Oral Doses Of CP- 690,550 And 1 Subcutaneous Dose Of Etanercept In Subjects With Moderate To Severe Chronic Plaque Psoriasis
Nov 15, 2011Purpose: To evaluate the efficacy of CP-690,550 as compared to etanercept and the safety of CP-690,550 for treatment of moderate to severe chronic plaque psoriasis.
Clinical Studies - Nov 15, 2011 - Dec 1, 2013
Automatically Closed
Project leader: Anliker Mark
A Phase 3, Multi-Site, Open-Label Study Of The Long Term Safety And Tolerability Of 2 Oral Doses Of CP-690,550 In Subjects With Moderate To Severe Chronic Plaque Psoriasis
Nov 15, 2011The main objective of this study is to evaluate the long-term safety of CP-690,550 in patients being treated for moderate to severe chronic plaque psoriasis. This is an open label extension study available to patients who participated in one of the q...
Clinical Studies - Nov 15, 2011 - Apr 19, 2015
Automatically Closed
Project leader: Anliker Mark
Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy, Safety & Tolerability of Two Doses of ACT-128800, an Oral S1P1 Receptor Agonist, Administered up to Twenty-eight Weeks in Patients With Moderate to Severe Chronic Plaque Psoriasis
Oct 19, 2011This study will assess the efficacy, safety and tolerability of two doses of ACT 128800 in patients with moderate-to-severe chronic plaque psoriasis.
Clinical Studies - Oct 19, 2011 - Sep 19, 2012
Automatically Closed
Project leader: Anliker Mark
Registerstudie CARPE-CH chronisches Handekzem
Jul 19, 2011Mit dieser Studie sollen wichtige und bisher fehlende Daten zu chronischen Handekzemen strukturiert erhoben werden, durch die neue Erkenntnisse zur Ursache, Therapie und Prognose von Handekzemen zu erwarten sind. Insbesondere sollen dadurch Erkenntni...
Clinical Studies - Jul 19, 2011 - Jul 19, 2013
Automatically Closed
Project leader: Anliker Mark
A double-blind, randomized, placebo-controlled Phase III study to assess the efficacy of recMAGE-A3 + AS15 ASCI as adjuvant therapy in patients with MAGE-A3 positive resected stage III melanoma; Short Title: GSK 2132231A Antigen-Specific Cancer Immunotherapeutic as adjuvant therapy iin patients with resexted melanoma
Dec 22, 2010A double-blind, randomized, placebo-controlled Phase III study to assess the efficacy of recMAGE-A3 + AS15 ASCI as adjuvant therapy in patients with MAGE-A3 positive resected stage III melanoma; Short Title: GSK 2132231A Antigen-Specific Cancer Immun...
Fundamental Research - Dec 22, 2010 - Dec 31, 2015
Automatically Closed
Project leader: Heinzerling Lucie
clinical study; The tolerance of acid textiles (pH 5.5-6.5) in patients with atopic and/or dry skin - a randomized, double blind, placebo-controlled study conducted by Kantonsspital St. Gallen
Dec 22, 2010clinical study; The tolerance of acid textiles (pH 5.5-6.5) in patients with atopic and/or dry skin - a randomized, double blind, placebo-controlled study conducted by Kantonsspital St. Gallen
Clinical Studies - Dec 22, 2010 - Dec 22, 2010
Completed
Project leader: Heinzerling Lucie
Assessment of a novel lyophilizable virosome formulation as an adjuvant to the induction of effector cells specific for Melan-A/MART-1 melanoma associated antigen
Feb 1, 2010Die Zahl der Melanompatienten nimmt kontinuierlich zu. Wirksame Therapieansätze nach der chirurgischen Entfernung des Tumors fehlen leider. Chemotherapie und Strahlentherapie sind nur bedingt wirksam. Längst wurde erkannt, dass das menschliche Abwehr...
Fundamental Research - Feb 1, 2010 - Jan 31, 2011
Completed
Project leader: Adamina Michel
Members: Heinzerling Lucie, Weder Patrik
A Phase II, randomized, double-blind, placebo
Dec 7, 2009A Phase II, randomized, double-blind, placebo -controlled, multi-centre study of the savety and efficacy of CT 327, Pegylated K-252, formulated as a cream, when administered twice daily for 14 days to subjects with Mild-to-Moderate atopic Dermatit...
Clinical Studies - Dec 7, 2009 - Oct 30, 2010
Completed
Project leader: Heinzerling Lucie
A randomized, double-blind, placebo controlled Phase
Dec 7, 2009A randomized, double-blind, placebo controlled Phase II, multi-centre study of the efficacy and safety of CT 327, a topical cream formulation of Pegylated K252a, when administered twice daily for eight weeks to patients with mild to moderate Ps...
Clinical Studies - Dec 7, 2009 - Nov 25, 2010
Completed
Project leader: Heinzerling Lucie